Publications

The benefit of our technology is demonstrated and documented in peer-reviewed publications and scientific posters. We’re continually developing compelling scientific data on how the Farcast tumor microenvironment advances the oncology field.

The Farcast platform was founded on the technology and science produced by the findings of Mitra Biotech.

Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance

Science Signaling (August 2019)

Predicting clinical response to anticancer drug remains a major challenge in cancer treatment. Emerging reports indicate that the tumor microenvironment and heterogeneity can limit the predictive power of current biomarker-guided strategies for chemotherapy.

Integrating biological and mathematical models to explain and overcome drug resistance in cancer. Part 1: Biological facts and studies in drug resistance

Current Stem Cell Reports (August 2017)

Cancer stem cells (CSC) comprise (typically) a rare tumor subpopulation that contributes both intrinsic drug resistance and tumor reinitiation after therapy. Successful, durable cancer treatment is limited by drug resistance. Harnessing biology and math to simulate, study, and explain the mechanisms of resistance, by considering the whole tumor population, is providing new clues to overcome it.

Preclinical cancer models and biomarkers for drug development: New technologies and emerging tools

Journal of Molecular Biomarkers & Diagnosis (September 2017)

Predicting the efficacy of anticancer therapy is the holy grail of drug development and treatment selection in the clinic. We present a focused, brief perspective on emerging preclinical models for anticancer therapy that attempt to address the challenge posed by tumor heterogeneity, highlighting biomarkers of response and resistance.

Cancer immunotherapy and personalized medicine: Emerging technologies and biomarker-based approaches

Journal of Molecular Biomarkers & Diagnosis (September 2017)

We introduce new techniques that seek to tailor immunotherapy by reprogramming patient-autologous T-cells and new technologies that are emerging to predict clinical efficacy by mapping infiltration of lymphocytes and harnessing fully humanized platforms that reconstruct and interrogate immune checkpoint blockade, ex vivo.

Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition

Nature Communications (February 2015)

Using human breast cancer explants, in vitro cell lines, mouse in vivo studies, and mathematical modeling, here we show that exposure to a taxane induces phenotypic cell state transition towards a favoured transient CD44HI CD24HI chemotherapy-tolerant state.

Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2

Scientific Reports (February 2015)

KRAS mutation status can distinguish between metastatic colorectal carcinoma (mCRC) patients who may benefit from therapies that target the epidermal growth factor receptor (EGFR), such as cetuximab. These findings highlight the importance of integrating molecular profile and functional testing tools for optimization of alternate strategies in resistant populations.

Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity

Nature Communications (February 2015)

Predicting clinical response to anticancer drugs remains a major challenge in cancer treatment. Emerging reports indicate that the tumour microenvironment and heterogeneity can limit the predictive power of current biomarker-guided strategies for chemotherapy. Here we report the engineering of personalized tumour ecosystems that contextually conserve the tumour heterogeneity, and phenocopy the tumour microenvironment using tumour explants maintained in defined tumour grade-matched matrix support and autologous patient serums.

Posters

Translational efficacy of oncolytic HSV-1 in glioblastoma multiforme (GBM) using a human autologous ex vivo
platform, CANscript (AACR, 2019)

Superiority of response to carboplatin vs. cisplatin in combination with pembrolizumab vs. EXTREME for HNSCC, predicted by the ex vivo platform, CANscript (AACR, 2019)